Ac­tivist in­vestor push­es for man­age­ment over­haul, strate­gic re­view at Ther­a­vance

In a let­ter to Ther­a­vance Bio­phar­ma Mon­day morn­ing, ac­tivist in­vestor Irenic Cap­i­tal Man­age­ment pushed for sig­nif­i­cant changes to the board, a strate­gic re­view to weigh the po­ten­tial sale of the com­pa­ny or its as­sets, as well as cut­ting down on what it called ex­ces­sive share-based com­pen­sa­tion.

Irenic said that since Ther­a­vance spun out In­no­vi­va in 2014, its share­hold­ers have lost sig­nif­i­cant­ly on their in­vest­ment. The biotech had orig­i­nal­ly sep­a­rat­ed In­no­vi­va out to man­age the rev­enues it got from GSK on a num­ber of res­pi­ra­to­ry prod­ucts. The let­ter was first re­port­ed by Reuters.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER